Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 3/20 | 0.63 |
| ▸ | MC5R | P33032 | 3/20 | 0.63 |
| ▸ | MC3R | P41968 | 2/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | MC1R | Q01726 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | NPY1R | P25929 | 1/20 | 0.51 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5604920 | 0.90 | SLC6A4 (0.64) | MC4RMC5RMC3RSIGMAR1MC1R | |
| SCHEMBL7390289 | 0.86 | MC4R (0.55) | MC4RMC5RMC3RSIGMAR1MC1R | |
| SCHEMBL7383850 | 0.86 | MC4R (0.55) | MC4RMC5RMC3RSIGMAR1MC1R | |
| SCHEMBL7468937 | 0.85 | SLC6A2 (0.64) | SIGMAR1 | |
| SCHEMBL2444736 | 0.80 | DPP7 (0.69) | SIGMAR1KMT2A | |
| SCHEMBL2443705 | 0.78 | DPP7 (0.57) | HRH3HDAC1 | |
| SCHEMBL23121278 | 0.78 | MC5R (0.71) | MC4RMC5RMC3RMC1RHDAC3 | |
| SCHEMBL11922800 | 0.78 | MC5R (0.71) | MC4RMC5RMC3RMC1RHRH3 | |
| SCHEMBL31617941 | 0.78 | MC5R (0.71) | MC4RMC5RMC3RMC1RHDAC3 | |
| SCHEMBL30380055 | 0.78 | MC5R (1.00) | MC4RMC5RMC3RMC1RHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1809288-B1 | USE OF 1,4-BIS (3-AMINOALKYL) PIPERAZINE DERIVATIVES IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | INST NAT SANTE RECH MED (FR) | 2011-09-14 | — | — | EP | claimed |
| US-20090149464-A1 | Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases | UNIVERSITE DU DROIT ET DE LA SANTE- LILLE II (FR) | 2009-06-11 | — | — | US | claimed |
| EP-1809288-A1 | USE OF 1,4-BIS (3-AMINOALKYL) PIPERAZINE DERIVATIVES IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2007-07-25 | — | — | EP | claimed |
| WO-2006051489-A1 | USE OF 1,4-BIS (3-AMINOALKYL) PIPERAZINE DERIVATIVES IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2006-05-18 | — | — | WO | claimed |
| US-9044478-B2 | Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2015-06-02 | — | — | US | disclosed |
| EP-1809288-B1 | USE OF 1,4-BIS (3-AMINOALKYL) PIPERAZINE DERIVATIVES IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | INST NAT SANTE RECH MED (FR) | 2011-09-14 | — | — | EP | disclosed |
| US-20090149464-A1 | Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases | UNIVERSITE DU DROIT ET DE LA SANTE- LILLE II (FR) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149464-A1 | Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases | PSEN1, PSEN2, SNCA | MC4R 2898/4885MC5R 1871/4885MC3R 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.